Pharmacoeconomic review report. Cysteamine delayed-release capsules (Procysbi), Horizon Pharma Ireland Ltd.
Cysteamine (Procysbi), a delayed-release formulation containing 25 mg or 75 mg of cysteamine bitartrate (referred to as delayed-release cysteamine) was approved by Health Canada for the treatment of patients with nephropathic cystinosis. Cystinosis is a recessive autosomal genetic ultra-rare disease...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534498/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
